Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase 2A/2B Study to Compare the Efficacy and Safety of ASLAN001 + Capecitabine to Lapatinib + Capecitabine in Patients With HER 2-Positive MBC That Has Failed on Prior Trastuzumab Therapy

Trial Profile

Randomized Phase 2A/2B Study to Compare the Efficacy and Safety of ASLAN001 + Capecitabine to Lapatinib + Capecitabine in Patients With HER 2-Positive MBC That Has Failed on Prior Trastuzumab Therapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Varlitinib (Primary) ; Capecitabine; Lapatinib
  • Indications Advanced breast cancer; HER2 positive breast cancer
  • Focus Therapeutic Use
  • Sponsors ASLAN Pharmaceuticals
  • Most Recent Events

    • 31 May 2020 Results (n=35) of retrospective analysis assessing therapeutic response across treatment arms and different tumor location presented at the 56th Annual Meeting of the American Society of Clinical Oncology
    • 10 Sep 2019 According to an ASLAN Pharmaceuticals media release, data from this study will be presented at the upcoming ESMO Asia Congress 2019 in Singapore on 22 November to 24 November.
    • 21 Sep 2018 According to an ASLAN Pharmaceuticals media release, data from this study will be presented at the 21st Annual Meeting of Chinese Society of Clinical Oncology (CSCO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top